Coronary artery calcium score may be a novel predictor of COVID-19 prognosis: a retrospective study

Yuichiro Takeshita,1 Jiro Terada,1 Retsu Fujita,2 Yasutaka Hirasawa,1 Taku Kinoshita,1 Yuri Isaka,1 Toru Kinouchi,1 Hiroshi Tajima,1 Yuji Tada,1 Shigeru Kiryu,3 Kenji Tsushima1

ABSTRACT

Background Although several studies have reported an association between atherosclerosis-related diseases and COVID-19, the relationship between COVID-19 severity and atherosclerosis progression remains unclear. The aim of this study is to determine the coronary artery calcium score (CACS) prognostic value in patients with COVID-19 using indices such as deterioration in oxygenation and CT images of the chest.

Methods This was a single-centre retrospective study of 53 consecutive patients with COVID-19 in Narita who were admitted to our hospital between March 2020 and August 2020. CACS was calculated based on non-gated CT scans of the chest performed on admission day. The patients were divided into the following two groups based on CACS: group 1 (CACS ≥180, n=11) and group 2 (CACS <180, n=42). Following univariate analysis of the main variables, multivariate analysis of variables that may be associated with COVID-19 progression was performed.

Results Multivariable logistic regression analysis of age, sex, smoking history, diabetes, hypertension, dyslipidaemia, number of days from symptom onset to hospitalisation and CACS of ≥180 was performed. It revealed that unlike CACS of <180, CACS of ≥180 is associated with exacerbation of oxygenation or CT images of the chest during hospitalisation (OR: 12.879, 95% CI: 1.399 to 380.401). Furthermore, this model of eight variables showed good calibration (Hosmer-Lemeshow p=0.119).

Conclusion CACS may be a prognosis marker of COVID-19 severity. Although coronary artery calcification is not typically assessed in pneumonia cases, it may provide a valuable clinical indicator for predicting severe COVID-19 outcomes.

INTRODUCTION

COVID-19, which is caused by SARS-CoV-2, has spread rapidly worldwide and has become a pandemic. According to the WHO, COVID-19 dashboard, as of 3 March 2021, there were 114,653,749 confirmed cases of COVID-19 and 2,550,500 deaths due to COVID-19.12 Previous reports suggest that approximately 20% of patients with COVID-19 rapidly progress to a critical clinical condition.34
be quantified using the coronary artery calcium score (CACS). CACS is a widely used quantification score for atherosclerosis in cardiovascular medicine. Higher CACSs are associated with a higher risk of future cardiovascular events, providing a useful tool for predicting cardiovascular events. Only a few studies have pointed out the association between CAC and prognosis in hospitalised patients with COVID-19.

In this study, we aimed to determine the prognostic value of CACS in patients with COVID-19 using deteriorations of oxygenation and CT images of the chest during hospitalisation as indices.

**METHODS**

**Study design and subjects**

This was a single-centre retrospective study of consecutive patients with COVID-19 confirmed using quantitative reverse-transcription PCR test and admitted to our hospital (International University of Health and Welfare Narita Hospital) between March 2020 and August 2020. Of 92 patients admitted to our hospital in this period, 53 were enrolled into this study after excluding 32 patients who were under 39 years of age, 5 patients who did not undertake regular CT scans on admission, 1 patient who had agitation and 1 patient with insufficient data (figure 1).

**Clinical assessment**

The electronic medical records of the hospital were used to extract data during hospitalisation such as laboratory test results, CT scans, vital signs, peripheral capillary oxygen saturation (SpO₂), oxygen demand and patient characteristics including age (in years), sex, body mass index (BMI: in kg/m²), smoking history (current or former), CACS and comorbidities. The number of days from onset to admission to our hospital and the length of hospital stay were evaluated. Laboratory tests were performed on admission day, and regular inspections were conducted at least once a week during hospitalisation. CT scans were performed on all admitted patients with COVID-19. CT scans were performed on admission day, and regular inspections were conducted once a week or once every 2 weeks. In our hospital, deterioration of CT image of the chest was defined by postadmission CT scans showing progression of ground-glass opacity or infiltrative shadows. CT findings were evaluated for CACS and disease progression (eg, area of shadow and change of shadow type) by two skilled operators (one radiologist and one pulmonologist) blinded to the clinical history. Vital signs, SpO₂, and dose of oxygen were recorded every day. Deterioration of oxygenation was defined as an SpO₂ of ≤93% and increase in oxygen dose after admission. Disease severity was categorised according to the National Institutes of Health guidelines into asymptomatic or presymptomatic infection, mild illness, moderate...
illness, severe illness and critical illness. Asymptomatic or presymptomatic infection refers to infection characterised by positive virologic test for SARS-CoV-2 in patients who have no symptoms consistent with COVID-19. Mild illness refers to illness characterised by any of the various signs and symptoms of COVID-19 but not shortness of breath, dyspnoea or abnormal findings on CT images of the chest. Moderate illness refers to illness characterised by evidence of lower respiratory tract disease observed during clinical assessment or on CT image of the chest and an SpO₂ of ≥94% on room air at sea level. Severe illness refers to illness characterised by an SpO₂ of <94% on room air at sea level, the ratio of arterial partial pressure of oxygen to fraction of inspired oxygen of <300 mm Hg, a respiratory rate of >30 breaths per minute or lung infiltrates of >50%. Critical illness refers to illness characterised by respiratory failure, septic shock and/or multiple organ dysfunction. We scored each patient on the admission day and on the worst-condition day.

Computed tomography
Non-gated CT studies were performed using an 80-detector row CT scanner (Aquilion Prime, Cannon Medical Systems, Otawara, Japan). CT scan of the chest was routinely performed without contrast media for all patients at admission. The acquisition parameters were as follows: tube voltage of 120 kVp, automatic tube current modulation of 40–650 mA, collimation of 320 mm×0.5 mm, field of view of 230 mm and rotation time of 0.275 s. As for an image reconstruction algorithm, we used a deep-learning-based reconstruction technique (Advanced Intelligent Clear-IQ Engine).

Coronary artery calcium score
All images were transferred to a dedicated computer workstation (ZAIO server, ZAIO software, Tokyo, Japan), and we calculated CACS as described by Agatston et al. Cass was defined by an area with CT attenuation value above a threshold of 130 Hounsfield units in the four main coronary arteries (ie, left main, left anterior descending, left circumflex and right coronary arteries). A lesion score was determined based on the maximal CT number as follows: 1=130–199, 2=200–299, 3=300–399 and 4≥400 Hounsfield units. Scores were calculated for each region of interest by multiplying the density score and the area. The total CACS was determined by adding up each of these scores for all 20 slices.

Statistical analysis
For baseline variables, summary statistics were constructed using mean (SD), median (IQR), frequency distributions or proportions. A sensitivity analysis was performed based on the distribution of 53 patients’ CACS data, using area under the curve. Analyses were performed with cut-off values of 150, 180, 300 and 400, and as a result, 180 was set as the cut-off value. The patients were divided into the following two groups based on CACS: group 1 (CACS ≥180, n=11) and group 2 (CACS <180, n=42). For continuous variables such as age, BMI and CACS, we first compared the mean values (mean, SD, quartile) between the two groups. Then, normality test was performed using the Kolmogorov-Smirnov test (two sided) and Shapiro-Wilk test, and homoscedasticity was further tested using the F test. According to the distribution of data, the Welch t-test and Mann-Whitney test were performed.

Fisher’s exact test was used to determine the significance of differences in the proportions of groups. After the key characteristics of the variables were studied, a logistic regression model was fitted with age, sex, smoking status, diabetes, hypertension, dyslipidaemia, days from onset to hospitalisation and a CACS of ≥180. Statistical significance was defined by OR and 95% CIs. Analyses were conducted using SAS V.9.4 (SAS Institute).

Patient and public involvement
No patients were involved in setting the research questions, outcome measures or study design. No patients were asked to advice on interpretation or the presentation of results.

RESULTS
Patient basic characteristics
The basic clinical characteristics of the 53 patients in the two groups (ie, group 1: CACS ≥180, n=11 and group 2: CACS <180, n=42) are shown in table 1. Age was significantly higher in group 1 than in group 2. The mean CACS was 701.9 (SD=±397.4) and 23.8 (SD=±41.5) in group 1 and group 2, respectively, (p<0.01). No significant differences in sex, BMI, smoking status, diabetes, hypertension, dyslipidaemia, days from onset to hospitalisation and a CACS of ≥180. Statistical significance was defined by OR and 95% CIs. Analyses were conducted using SAS V.9.4 (SAS Institute).

Table 1 Characteristics

| Variable       | ≥180 (n=11) | <180 (n=42) | P value |
|----------------|------------|------------|--------|
| Age, years     | 70.6 (10.3)| 61.3 (12.6)| 0.03   |
| Male sex       | 5 (45.5%)  | 21 (50%)   | 1      |
| BMI, kg/m²     | 24.6 (4.2)| 24.7 (3.9)| 0.978  |
| Smoking history| 4 (36.4%)  | 10 (23.8%) | 0.453  |
| Diabetes mellitus| 5 (45.5%)| 8 (19%)    | 0.112  |
| Hypertension   | 5 (45.5%)  | 16 (38.1%) | 0.736  |
| Dyslipidaemia  | 4 (36.4%)  | 10 (23.8%) | 0.453  |
| Heart disease  | 3 (27.3%)  | 6 (14.3%)  | 0.372  |
| Brain disease  | 3 (27.3%)  | 4 (11.9%)  | 0.34   |
| Lung disease   | 3 (27.3%)  | 8 (19%)    | 0.678  |
| Malignant tumour| 4 (36.4%)| 1 (2.4%)   | 0.372  |

Mann-Whitney U test was used to analyse CACS, t-test was used to analyse age and BMI, and Fisher’s exact test was used to analyse all other items. Mean (SD), median (IQR) or n (%). BMI, body mass index; CACS, coronary artery calcium score.
lungs disease or malignant tumour were observed between the two groups.

**Association between CACS and coronary risk factors**

The relationships between CACS and clinical parameters in patients with coronary risk factors are shown in figure 2. The median (IQR) CACS was significantly higher in patients with diabetes than in those without diabetes (74.4 (14.73–287.6) vs 2.5 (0–58.23), p=0.03, figure 2C). A weak positive correlation was observed between CACS and age ($\rho=0.282$, $p=0.039$, figure 2F). There was no significant association between CACS and sex, hypertension, dyslipidaemia or smoking status.

**Patients’ clinical characteristics before and after hospitalisation**

Patients’ clinical characteristics before and after hospitalisation are shown in table 2. Oxygenation or CT image of the chest deteriorations during hospitalisation were significantly worse in group 1 than in group 2 ($p=0.03$). Separate comparisons of deteriorations in oxygenation and CT images of the chest during hospitalisation showed a higher rate of deterioration in group 1 than in group 2, but there was no statistically significant difference between the two groups. Similarly, there was no statistically significant difference in disease severity at admission between the two groups. Further, the deterioration frequency during hospitalisation was higher in group 1 than in group 2, but there was no statistically significant difference between the two groups.

**CACS and deterioration of oxygenation or CT images of the chest during hospitalisation**

Table 3 reports the ORs and 95% CIs from logistic regressions of the deterioration of oxygenation or CT images of the chest during hospitalisation, adjusting factors such as
age, sex, smoking status, diabetes, hypertension, dyslipidaemia, days from onset to hospitalisation and a CACS of ≥180. A CACS of ≥180 was found to be associated with deterioration of oxygenation or CT images of the chest during hospitalisation (OR: 12.879, 95% CI: 1.399 to 380.401, Hosmer-Lemeshow p=0.119).

**DISCUSSION**

The main finding of this study is that in hospitalised patients with COVID-19, high CACS may be more strongly associated with deterioration of oxygenation and CT images of the chest than other general risk factors of atherosclerosis such as age, sex, smoking, dyslipidaemia, diabetes and hypertension.

Multivariate analysis revealed that high CACS is associated with COVID-19 progression and may be a prognostic predictor of COVID-19 severity. In the current state of the pandemic, prediction of COVID-19 prognosis using preclinical data (eg, age, smoking history and underlying medical history) and clinical information at the time of admission (eg, laboratory test and CT scan) is important in clinical settings. In this regard, the results of this study support the potential usefulness of CACS as an additional prognostic predictor that uses information from a widely available non-invasive modality (ie, CT of the chest).

Two earlier studies published in 2020 reported an association between CAC and COVID-19. In a single-centre cohort study of 53 hospitalised patients with COVID-19 in Italy, half of the patients with a CACS of ≥400 died during hospitalisation, whereas 8.9% of patients with a CACS of <400 died during hospitalisation. Using Kaplan-Meier analysis, a cross-sectional study in France of 209 consecutive patients hospitalised with COVID-19 and aged 40–80 years showed that CAC is associated with the first occurrence of non-invasive or invasive mechanical ventilation, extracorporeal membrane oxygenation or death during hospitalisation (HR: 3.5; 95% CI: 2.2 to 5.8; p<0.0001).

**Table 2** Clinical characteristics of patients before and after hospitalisation

| Variable                                 | CACS ≥180 (n=11) | CACS <180 (n=42) | P value |
|------------------------------------------|------------------|------------------|---------|
| Days from symptom onset to hospitalisation | 6 (1.5–12.5)     | 4.5 (1.0–6.8)    | 0.265   |
| Length of hospital stay                  | 22.4 (6.9)       | 18.1 (8.3)       | 0.112   |
| SpO2/FiO2 on admission                   | 461.9 (447.6–464.3) | 457.1 (448.8–461.9) | 0.816   |

**Table 3** CACS and deterioration of oxygenation or CT images of the chest during hospitalisation

| Factor                        | OR    | 95% CI     |
|-------------------------------|-------|------------|
| Age                           | 1.013 | 0.951 to 1.080 |
| Sex (male)                    | 1.093 | 0.215 to 5.609 |
| Smoking history               | 2.738 | 0.389 to 24.239 |
| Diabetes                      | 5.111 | 0.871 to 47.919 |
| Hypertension                  | 1.08  | 0.237 to 5.050 |
| Dyslipidaemia                 | 1.053 | 0.092 to 2.918 |
| Days from onset to hospitalisation | 0.829 | 0.686 to 0.957 |

CACS, coronary artery calcium score.;
In this study, the rate of oxygenation or CT image of the chest deterioration after admission was significantly higher in group 1 than in group 2. In addition, although the difference between the two groups was not statistically significant, the rates of deterioration of oxygenation, CT images of the chest and disease severity were higher in group 1 than in group 2. This suggests that CACS is a prognostic predictor of COVID-19 progression.

Other atherosclerosis-related comorbidities and unhealthy habits such as cerebrovascular disease, diabetes, hypertension and smoking are also known to be associated with COVID-19 severity, and this association may involve vascular endothelial dysfunction. Endothelial dysfunction is mainly observed in patients with comorbidities that increase the risk of COVID-19 disease progression. These comorbidities include hypertension, obesity, diabetes, coronary artery disease and heart failure. SARS-CoV-2 infection occurs in such a vascular condition, indicates that age is one of the strongest risk factors which predicts coronary disease using risk factor categories, subgroup of patients over the age of 40. The Suita score, CACS testing may be considered in adults aged 40–75 years. Second, all the patients’ CT images of the chest and disease severity were higher in group 1 than in group 2. In addition, although no statistically significant differences in age, smoking status, diabetes and hypertension were observed between the two groups, there is a higher tendency for disease progression in patients with a CACS of ≥180 than in patients with a CACS of <180.

Our study has several limitations. First, the study is of a subgroup of patients over the age of 40. The Suita score, which predicts coronary disease using risk factor categories, indicates that age is one of the strongest risk factors of coronary heart disease over any 10-year period. It also shows that the risk of coronary heart disease increases after the age of 35–44 years. The 2018 multisociety guidelines on cholesterol management also suggest that CACS testing may be considered in adults aged 40–75 years. Second, all the patients’ CT images of the chest were subjectively evaluated by clinicians. Further, changes in the pneumonia image during the clinical course were primarily and subjectively judged in clinical practice. Third, the CT scans were non-electrocardiography (ECG) gated. Moreover, CACS measured on non-ECG-gated CT scan is similar to CACS measured on ECG-gated CT scan. Fourth, in our study, the CACS cut-off of 180 was determined using area under the curve, which was not highly accurate (0.609, 95% CI: 0.461 to 0.756). However, a CACS of 180 is itself clinically significant. A high CACS is known to be associated with high coronary event rate and high relative risk ratio. Generally, a CACS of 1–112 is considered to be of average risk (risk ratio, 1.9), a CACS of 100–400 is considered to be of moderate risk (risk ratio, 4.3), a CACS of 400–999 is considered to be of high risk (risk ratio, 7.2) and a CACS of ≥1000 is considered to be of very high risk (risk ratio, 10.8). Our sensitivity analysis was performed based on the distribution of our CACS data, which resulted in selecting 180 as the cut-off value. In an atherosclerosis study, Budoff et al recommended setting the CACS cut-off value in the range of 100–400; thus, the value of 180 was deemed appropriate. However, the cut-off value determination could be considered a limitation of this retrospective study. Further studies are desirable to evaluate the validity of the cut-off value. Fifth, our results show that 36.4% of patients with an elevated CACS had a malignant tumour (table 1). In a previous report on the link between smoking-related cancers and CACS, the extent of coronary atherosclerosis determined by CACS was not generally associated with the development of cancer; however, an association between CACS and risk of lung cancer in women was detected. In our study, the number of patients with malignent tumours was small (n=5) and variable (prostate, colorectal, stomach and breast); thus, the potential association is unclear. Further research is needed to clarify the relationship between malignant tumours and CACS.

In conclusion, CACS may provide a useful non-invasive biomarker for predicting severe COVID-19 outcomes. CACS is not routinely evaluated in CT images of the chest, but in patients with COVID-19, it may be an important finding that can be used to predict prognosis.
information. All data relevant to the study are included in the article or uploaded as supplementary information. Data are available upon reasonable request.

Open access. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1 World Health organization who coronavirus diseasea 2019 (COVID-19) dashboard (data updated 2021/3/4) https://covid19.who.int/
2 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA 2020;323:1239–42.
3 Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020;288:192–206.
4 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020;383:2451–60.
5 Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19, 2020. Available: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html
6 Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–8.
7 Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1581 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020;323:1574–81.
8 Nishiga M, Wang DW, Han Y, et al. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Circulation 2020;141:1116–1124.
9 Kuno T, Takahashi M, Obata R, et al. Cardiovascular comorbidities, cardiac injury, and prognosis of COVID-19 in New York City. Am Heart J 2020;226:24–5.
10 Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32.
11 Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of cardiology Foundation clinical expert consensus Task force (ACCF/AHA writing Committee to update the 2000 expert consensus document on electron beam computed tomography) developed in collaboration with the Society of atherosclerosis imaging and prevention and the Society of cardiovascular computed tomography. J Am Coll Cardiol 2007;49:378–402.
12 Greenland P, Blaha MJ, Budoff MJ, et al. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol 2018;72:434–47.
13 Dillinger JG, Benmessaud FA, Pezel T, et al. Coronary artery calcification and complications in patients with COVID-19. JACC Cardiovasc Imaging 2020;13:2468–70.
14 Nai Fovino L, Cademartiri F, Tarantini G. Subclinical coronary artery disease in COVID-19 patients. Eur Heart J Cardiovasc Imaging 2020;21:1055–6.
15 An official website of the National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines: clinical spectrum of SARS-CoV-2 infection (last updated: December 17, 2020), 2020. Available: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
16 Dreyer KJ, Geis JR. When machines think: radiology’s next frontier. Radiology 2017;285:713–8.
17 Chen H, Zhang Y, Zhang W, et al. Low-Dose CT via convolutional neural network. Biomed Opt Express 2017;8:679–94.
18 Mori H, Torii S, Kutsyna M, et al. Coronary Artery Calcification and its Progression: What Does it Really Mean? JACC Cardiovasc Imaging 2018;11:127–42.
19 Nägele MP, Haubner B, Tanner FC, et al. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis 2020;314:58–62.
20 Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet 2020;395:1417–8.
21 Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005;111:2605–10.
22 Viola J, Soehnlein O. Atherosclerosis - A matter of unresolved inflammation. Semin Immunol 2015;27:184–93.
23 Nishimura K, Okamura T, Watanabe M, et al. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the Framingham risk score: the Suitsa study. J Atheroscler Thromb 2016;23:1138–9.
24 Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American heart association Task force on clinical practice guidelines. Circulation 2019;139:e1082–143.
25 Budoff MJ, Nast K, McColland RL, et al. Coronary calcium predicts events better with absolute calcium scores than age-sex-race/ethnicity percentiles: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2009;53:345–52.
26 Vinter N, Christensen AMS, Mortensen LS, et al. Relation of coronary artery calcium score and risk of cancer (from a Danish population-based follow-up study in patients who underwent cardiac computed tomography). Am J Cardiol 2017;120:542–9.